Acadian Asset Management LLC Purchases 720,629 Shares of Agenus Inc. (NASDAQ:AGEN)

Acadian Asset Management LLC lifted its position in Agenus Inc. (NASDAQ:AGEN - Free Report) by 1,959.9% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 757,397 shares of the biotechnology company's stock after buying an additional 720,629 shares during the period. Acadian Asset Management LLC owned about 3.73% of Agenus worth $439,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Agenus by 1.6% during the 3rd quarter. Vanguard Group Inc. now owns 26,938,439 shares of the biotechnology company's stock worth $30,440,000 after purchasing an additional 432,202 shares in the last quarter. SG Americas Securities LLC increased its holdings in Agenus by 526.6% during the 4th quarter. SG Americas Securities LLC now owns 198,735 shares of the biotechnology company's stock worth $165,000 after purchasing an additional 167,017 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in Agenus by 3,008.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,306,248 shares of the biotechnology company's stock worth $1,909,000 after purchasing an additional 2,232,064 shares in the last quarter. PCG Wealth Advisors LLC increased its holdings in Agenus by 65.7% during the 4th quarter. PCG Wealth Advisors LLC now owns 47,550 shares of the biotechnology company's stock worth $39,000 after purchasing an additional 18,850 shares in the last quarter. Finally, Cardinal Strategic Wealth Guidance increased its holdings in Agenus by 28.2% during the 4th quarter. Cardinal Strategic Wealth Guidance now owns 910,265 shares of the biotechnology company's stock worth $754,000 after purchasing an additional 200,000 shares in the last quarter. Institutional investors own 61.46% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on AGEN shares. HC Wainwright cut Agenus from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $40.00 to $9.00 in a report on Thursday, July 18th. StockNews.com started coverage on Agenus in a report on Wednesday, April 17th. They set a "hold" rating for the company. Robert W. Baird cut Agenus from an "outperform" rating to a "neutral" rating and decreased their price objective for the company from $35.00 to $8.00 in a report on Friday, July 19th. William Blair cut Agenus from an "outperform" rating to a "market perform" rating in a report on Thursday, July 18th. Finally, Jefferies Financial Group restated a "hold" rating and issued a $7.00 price objective (up previously from $3.00) on shares of Agenus in a report on Friday, July 19th. Six research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $31.00.

Check Out Our Latest Stock Analysis on AGEN

Agenus Price Performance

Shares of NASDAQ AGEN opened at $6.56 on Friday. Agenus Inc. has a fifty-two week low of $4.78 and a fifty-two week high of $32.00. The stock has a market capitalization of $137.75 million, a price-to-earnings ratio of -0.51 and a beta of 1.32. The business has a 50-day moving average of $13.90 and a 200-day moving average of $12.52.

Agenus (NASDAQ:AGEN - Get Free Report) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($3.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.58) by $0.54. The firm had revenue of $28.01 million during the quarter, compared to analyst estimates of $40.70 million. On average, sell-side analysts expect that Agenus Inc. will post -10.73 EPS for the current year.

Agenus Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Featured Articles

• Five stocks we like better than Agenus
• 3 Ways To Invest In Coffee, Other Than Drinking It
• Why Call Options Volume for These 2 Stocks Spiked Together
• What is Put Option Volume?
• MarketBeat Week in Review – 7/22 - 7/26
• How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
• 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ 625,000% Gain (From Crypto Swap Profits) (Ad)

Should you invest $1,000 in Agenus right now?

Before you consider Agenus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.

While Agenus currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here